Fig. 5.

TNFR2 antagonist enables continuous dose-dependent T_eff expansion in Sézary syndrome patient samples. a Proportion of T_eff cells from patients (n = 18 samples) after incubation of freshly isolated CD4⁺ cells with IL-2 and TNFR2 antagonist (0–125 µg/ml) for 48–72 h. b Proportion of T_eff cells from controls (n = 11) as described in a. c Relative change in T_eff of patients and controls after culture with TNFR2 antagonist as described in a. d Comparison of baseline proportions of T_eff from patients and controls. Data are mean ± SEM, asterisks indicate significant difference from baseline (TNFR2 antagonist 0.1 µg/ml; t test p < 0.05), and underlined asterisks indicate significant difference in patients versus controls (Z test 95%CI)